

39th Annual North American Cystic Fibrosis Conference

October 22-25, 2025
Seattle Convention Center, Summit Building
Seattle, Washington



Emory + Children's CF Center of Excellence (CF@LANTA) and
Center for CF & Airways Disease Research (CF-AIR)



Presentation Schedule and Information

Thursday, October 23, 2025

Time / Location	Topic / Representative
7:45 - 9:45 am PDT Location: 320-322	DG09--Metabolic Health & Cardiovascular Disease Risk Speaker: Jessica A. Alvarez, PhD, RD (she/her/hers) – Emory University School of Medicine
9:00 - 9:45 am PDT Location: Theater B Exhibit Hall	RFPT01-- Therapeutic Targeting of Inflammation in CF Chair: Benjamin T. Kopp, MD, MPH – Emory University/Children's Healthcare of Atlanta
10:15 am - 12:15 pm PDT Location: Signature Room	W06.5- Modifiable predictors of Beta-cell function in adults with CF: The role of body composition and sugar intake Speaker: Tancia C. Daley, MD, MPH – Emory University
10:15 am - 12:15 pm PDT Location: 420-422	W11--Topical Advancements in CFTR Biology Chair: Kathryn E. Oliver, PhD, MS, CPTS – Emory University School of Medicine
10:15 am - 12:15 pm PDT Location: 420-422	W11.3- Role of cholesterol on CFTR single channel characteristics and potential cholesterol binding domains Speaker: Jonica Brown – Emory University
10:15 am- 12:15 pm PDT Location: 423-425	W14--Management of Infections & Inflammation in CF Chair: Irina Miralda Molina, PhD – Emory University
10:15 am -12:15 pm PDT Location: Ballroom 3	W15--New Horizons in CF Newborn Screening: Advancements & Updates Chair: Rachel Linnemann, MD – Department of Pediatrics, Division of Pulmonology, Asthma, Cystic Fibrosis, and Sleep, Emory University School of Medicine
12:30 pm - 1:20 pm PDT Location: Theater B Exhibit Hall	RFPT03.3- Screening for patterns of disordered eating and body image disorders in adults with CF Speaker: Caitlin Bascle, RDN, LD – Emory Healthcare

12:30 - 2:30 pm PDT
Location: Poster Hall

Junior Investigators: Top 10 Poster Judging Time
Chair: Kathryn E. Oliver, PhD, MS, CPTS – Emory University School of Medicine

Poster Presenters:

Irina Miralda Molina, PhD—Emory University
Su Yeoh Oh--Nutrition and Health Sciences Doctoral Program, Laney Graduate School, Emory University
Jiafeng (Stuart) Song, M.Sc. – Duke University

12:30 pm - 2:00 pm PDT
Location: 347-348

LL01--So Many Guidelines, So Little Time
Chair and Speaker: Brandi Middour-Oxler, DNP, CPNP – Emory University School of Medicine

1:30 pm - 2:20 pm PDT
Location: Theater B
Exhibit Hall

RFPT05.6- Characterization of bacteriophages that lyse diverse cystic fibrosis *Stenotrophomonas maltophilia* complex isolates
Speaker: Cristian V. Crisan – Emory University School of Medicine

2:30 - 4:00 pm PDT
Location: Theater A
Exhibit Hall

TPS03.8- Body fat distribution impacts glucose and insulin secretory indices in people with CF
Speaker: Lucia Gonzalez Ramirez – Emory University

2:30 pm - 4:30 pm PDT
Location: 423-425

S05.4- The CF carrier advantage: were CFTR mutations selected along human evolution and why
Speaker: Rabindra Tirouvanziam, PhD – Department of Pediatrics, Emory University

2:30 PM - 4:30 pm PDT
Location: 435

S06--Cure (or Close) for All
Chair: Tanicia C. Daley, MD, MPH – Emory University

7:00 - 9:00 pm PDT

CF@LANTA Reception
Flatstick Pub – South Lake Union
609 Westlake Avenue N, Seattle, WA 98109

Connect with colleagues, celebrate our community's work, and enjoy some time together in Seattle. Food will be provided.

Friday, October 24, 2025

Time / Location

Topic / Representative

7:45 - 9:45 am PDT
Location: Flex A

PF3- The comeback kid: Pulmonary and pancreatic restoration in a school-aged child with CF on long-term highly effective modulator therapy
Speaker: Kristen Facey Holligan, MBBS, FAAP – Emory University / Children's Healthcare of Atlanta

7:45 - 9:45 am PDT
Location: Signature Room

W16.1- Hidden in plain sight: Rediscovering Mast Cells in CF
Speaker: Irina Miralda Molina, PhD – Emory University

10:15 am - 12:15 pm PDT
Location: 435

W18.3- Equitable care: MyChart Spanish
Speaker: Michelle McKinnon, MSN, CPNP-PC – Children's Healthcare of Atlanta

10:15 am - 12:15 pm PDT Location: 436	W22.1- Bioenergetic and metabolic derangements in circulating CF neutrophils are further enhanced by transmigration to the CF airway milieu Speaker: Kathryn M. Crotty, PhD – Emory University
10:15 am - 12:15 pm PDT Location: 436	W22.2- Chronic CF airway disease is driven by MALAT1+ extracellular vesicles via an HDAC11-dependent mechanism Speaker: Brian Dobosh – Emory University
10:15 am - 12:15 pm PDT Location: 436	W22.3- LAP it up: The role of LC3 Associated Phagocytosis (LAP) in CF Speaker: Mahesh K. Shrestha, MS, MBA – Emory University
12:30 - 1:30 pm PDT Location: 347-348	Junior Investigators Competition: Top 5 Best Abstract in Basic Science Chair: Kathryn E. Oliver, PhD, MS, CPTS – Emory University School of Medicine
2:30 - 4:30 pm PDT Location: 435	S19.3- Sweat Signals: Use of Sweat Chloride in Clinical Trials of CFTR Modulators Speaker: Rachel Linnemann, MD – Department of Pediatrics, Division of Pulmonology, Asthma, Cystic Fibrosis, and Sleep, Emory University School of Medicine
2:30 - 4:30 pm PDT Location: Terrace Suite	S20.3- Beyond the Channel: Immune Implications of CFTR Modulation Speaker: Benjamin T. Kopp, MD, MPH – Emory University/Children's Atlanta
2:30 - 4:30 pm PDT Location: 433-434	S23.4- Updates in Pain and Review of Recent Guidelines Speaker: Dio Kavalieratos, PhD – Emory University

Poster Session – Friday, October 24th, Odd Numbered Posters

12:15 - 1:15 pm PDT	Poster 15: <i>Characterization of bacteriophages that lyse diverse cystic fibrosis Stenotrophomonas maltophilia complex isolates.</i> C. Crisan, R. Robinson, D. Van Tyne, J. Goldberg. Poster 21: <i>The impact of modulator therapy on the Pseudomonas aeruginosa CF lung transcriptome.</i> M. Letizia, L. Whiteley, F. Diggle, E. McKone, P. Singh, M. Whiteley. Poster 27: <i>Experimentally evolving a Staphylococcus aureus cystic fibrosis isolate to resist its co-isolated Pseudomonas aeruginosa.</i> J. Luu, J. Goldberg. Poster 45: <i>Overcoming barriers to treating Pseudomonas aeruginosa: monoclonal antibodies targeting elongation factor-Tu (EF-Tu), a feasible and efficacious therapeutic approach.</i> D. Moustafa*, M. Mateu-Borrás*, M. Verd, T. Bernabé, A. Doménech-Sánchez, J. Wrammert, S. Albertí, J. Goldberg. Poster 67: <i>Bile acids as immunomodulatory signals in cystic fibrosis.</i> S. Durfey, H. Ozuna, J. Moran, M. Shrestha, I. Miralda Molina, B. Kopp. Poster 79: <i>Selection scan reveals algG as a putative driver of Pseudomonas aeruginosa survival in the post-ETI lung.</i> T. Jia, L. Whiteley, Y. Chen, S. Durfey, S. Morgan, M. Radey, P. Singh, A. Feder.
---------------------	---

Poster 119: *Maximizing benefits with early CFTR modulator treatment: Lower sweat chloride is associated with improved clinical outcomes in children aged 6 to 11 years.* R. Linnemann, E. Zemanick, G. Davies, F. Stehling, E. McKone, E. Tullis, J. Taylor-Cousar, F. Van Goor, E. Arteaga-Solis, N. Nair, K. Krone, B. Ramsey, M. Mall.

Poster 135: *Assessing infection and inflammation in cystic fibrosis through exhaled breath: a longitudinal study.* J. Ackah-Cudjoe, A. Gao, M. Hashemi, S. Durfey, E. McKone, P. Singh, J. Hill.

Poster 137: *Effects of a specialist palliative care vs usual care among adults living with CF: a multisite randomized phase III clinical trial of the InSPIRe:CF intervention.* D. Kavalieratos, J. Lowers, R. Arnold, A. Stephenson, C. Hovater, J. Goggin, M. Bakitas, J. Soodalter, W. Hunt, L. Hanson, T. Wang, K. Jeong, J. Ailon, K. Curseen, S. Barrett, G. Solomon.

Poster 145: *Implications of hypoxia-induced changes in regional airway lipid composition and biophysical properties in cystic fibrosis.* N. Stevens, G. Clair, M. Raiha, H. Murano, A. Cawley, C. van Heusden, Z. Wisniewski, A. Singh, M. Furusho, E. Burns, H. Dang, S. Randell, W. O'Neal, Y. Mikami, S. Danielsen, D. Hill, R. Boucher, K. Okuda.

Poster 147: *Mucin interactions at the air-liquid interface.* M. Raihan, F. Fazelpour, S. King, N. Stevens, K. Okuda, W. Kissner, S. Danielsen, B. Button, M. Rubinstein, D. Hill.

Poster 177: *Host-driven mechanisms of bacterial tolerance in cystic fibrosis airway disease.* D. Luthra, B. Dobosh, J. Hosten, R. Tirouvanziam.

Poster 195: *LAP it up: The role of LC3 Associated Phagocytosis (LAP) in cystic fibrosis (CF).* M. Shrestha, B. Kopp, A. Murphy, C. Shrestha.

Poster 199: *Bioenergetic and metabolic derangements in circulating CF neutrophils are further enhanced by transmigration to the CF airway milieu.* K. Crotty, G. Collins, J. Lyles, J. Chandler.

Poster 213: *Red blood cell-derived nanoparticles as drug carriers to human airway neutrophils in cystic fibrosis.* S. Padmanabhan, B. Dobosh, P. Kumar, R. Tirouvanziam.

Poster 247: *Targeted gene insertion for functional CFTR restoration in cystic fibrosis airway epithelium.* C. Barilla, S. Suzuki, S. Park, D. Nalluri, H. Wen, M. Hanafy, A. Umrigar, S. Leir, K. Lovrenert, A. Sivachenko, B. Tabak, H. Valley, A. Rab, E. Sorscher, G. Solomon, J. Carulli, A. Harris, G. Bao, B. Davis.

Poster 261: *Functional restoration of yeast Yor1 models of CF-causing alleles: mutation-specific assessment of genetic and pharmacologic strategies.* R. Mancinone, E. Gaines, D. Buchanan, J. Hong, E. Sorscher, J. Hartman.

Poster 315: *CFTR allelic skewing as a contributor to cystic fibrosis clinical phenotype and modulator response.* M. Freyberg, M. Bewig, G. Bavia Bampi, C. Manfredi, D. Joshi, R. Rauscher, J. Hong, J. Große-Onnebrink, S. Sutharsan, F. Stehling, I. Bobis, M. Ballmann, E. Sorscher, Z. Ignatova.

Poster 317: *Dual potentiator and corrector activity of CFTR modulators when treating W1282X CFTR in cell-based systems.* C. Manfredi, A. Rab, D. Joshi, K. Oliver, S. Molina, M. Koval, N. Khazanov, M. Jacobson, H. Senderowitz, E. Sorscher, J. Hong.

Poster 323: *CFTR-F508del leads to metabolic dysregulations in 16HBE cells.* X. Ji, G. Cui, S. Chen, N. McCarty.

Poster 371: *Equitable care: MyChart Spanish.* M. McKinnon, M. House, O. Ries, J. McNeany, M. Duval, M. Hazen, R. Linnemann.

Poster 397: *Intersectional lived experiences of LGBTQIA+ people with cystic fibrosis: a qualitative interview study.* R. Salyer, A. Alpern, A. Prangle, S. Rashid, A. Mitchell, O. Stransky, V. Tangpricha, J. Greenberg, P. Community Partner Group, G. Sawicki, T. Kazmerski, K. Kidd.

Poster 427: *Modulating the message: improving education about newborn screening after exposure to CFTR modulators.* St Onge, A. Ladner, S. Brown, A. Watson, J. Philippon, N. Montag, M. Dumas, C. Coyne, J. D Amico, J. Zuckerman, K. Rutledge.

Poster 431: *Impact of an educational toolkit on provider knowledge and understanding of abnormal newborn screen for cystic fibrosis in the state of Georgia.* N. Wimmer, B. Fisher, K. McKie.

Poster 441: *Improving Life with CF: feasibility and adult outcomes from a multi-site US primary palliative care trial.* A. Georgiopoulos, S. DiFiglia, E. Seng, R. Portenoy, N. Chaudhary, J. Wang, P. Walker, B. Middour-Oxler, R. Linnemann, C. Kier, D. Friedman, B. Diener, M. Berdella, J. Trentacoste, T. Stables-Carney, A. Plachta, K. Papia, T. Frantzen, C. Esposito, L. Yonker R. Wei, T. Mullen, L. Dhingra.

Poster 451: *Unmet care needs among adults with CF in the modulator era: findings from the InSPIRe: CF multisite clinical trial.* J. Lowers, C. Hovater, E. Dellon, A. Stephenson, J. Goggin, M. Bakitas, K. Curseen, J. Soodalter, W. Hunt, S. Barrett, G. Solomon, L. Hanson, J. Ailon, R. Arnold, D. Kavalieratos.

Poster 455: *Electronic medical record approach to enhance recruitment of individuals with cystic fibrosis for a dietary intervention trial.* S. Zaveri, G. Najarro, M. Niyibizi, B. Chan, M. Schwinne, A. Stecenko, W. Hunt, K. Easley, W. Driggers, T. Ziegler, T. Daley, P. Vellanki, J. Alvarez.

Poster 515: *ACT with CF self-help toolkit.* C. O'Hayer, C. Drescher, H. Bruschwein, K. Ingle, E. Wakschal, P. Smith.

Poster 529: *Baseline results from the NEMO study: psychometric evaluation of the preschool cystic fibrosis questionnaire-revised in children with cystic fibrosis and caregivers in the United States and Australia.* J. Chmiel, Q.Do, M.Dowell, A. Tai, B. Clements, D. Armstrong, A. Kasi, C.Mo, L. Zhu, M. Jennings, A. Quittner, C. Wainwright.

Poster 565: *Screening for patterns of disordered eating and body image disorders in adults with CF.* C. Bascle.

Poster 599: *Baseline body composition and sarcopenia measures of adults with preserved lung function in the STRONG-CF Study.* H. Fonseca, Z. Reed, J. Alvarez, S. Freedman, S. Schwarzenberg, J. Sibayan, A. Stein, J.Clancy.

Poster 603: *Factors guiding decision-making about gastrostomy tube placement among caregivers of children with cystic fibrosis: a scoping review.* K. Dickinson, A. Rahimian, N. Givens, K. Goebel, C. Ohamadike.

Poster 609: *Strategies to optimize nutritional status in adult cystic fibrosis – a QI initiative.* G. Nageswaran, S. Lazaro, R. Joshi, D. Kelly, E. Jones, C. Forseen, V. Taskar.

Poster 697: *Impact of abnormal glucose tolerance on plasma redox metabolites in cystic fibrosis.* S. Oh, S. Kim, J. Lyles, W. Hunt, N. McCarty, T. Daley, A. Stecenko, T. Ziegler, J. Alvarez, J. Chandler.

Poster 699: *Dynamic time warping analysis of continuous glucose monitoring reveals significant dysglycemia that is underestimated by oral glucose tolerance test classification.* J. Song, J. Alvarez, T. Daley, S. Gillespie, R. Harris, J. McNeany, R. Kamaleswaran, A. Stecenko.

Poster 791: *Expanded use of remote objective monitoring during telehealth visits for people with CF experiencing acute symptoms: The EUROPA Project.* N. Lechtzin, W. Hunt, C. Forseen, G. Hong, P. Mogayzel, K. McKie, D. Peeler, M. Phillips, M. Rey, O. Ries, V. Taskar, N. Wimmer.

Poster 795: *Standardizing CFRD care: A quality improvement approach to glucose monitoring and care in pediatric cystic fibrosis patients.* K. McKie, N. Smith, M. Poisson, N. Wimmer, E. Carrick.

Poster 797: *Fat matters: Improving lipid screening in pediatric cystic fibrosis program.* M. Martin, D. Batchelder, M. Cook, K. Patel, O. Ries, B. Baxter, M. McKinnon, S. Pendley, C. Bethune, M. House, L. Guglani, M. Hazen, R. Linnemann.

Poster 837: *Establishing a process for lung transplant referral and advanced care planning at the Geisinger Adult Cystic Fibrosis Program: a quality improvement initiative.* J. Moyo, C. Shoff, H. Brosius, B. Ritter, C. Tsai, L. Wright, S. Pritt, D. Tejwani.

1:15 - 2:15 pm PDT

Poster 6: *Hidden in plain sight: rediscovering mast cells in cystic fibrosis.* I.Miralda, J.Moran, M. Shrestha, H. Ozuna, S. Durfey, B. Kopp.

Poster 38: *O-specific antigen-deficient Pseudomonas aeruginosa reshape microbiogeography of mixed populations in pulmonary infection.* S. Azimi, H. Fraser, D. Moustafa, J. Goldberg.

Poster 100: *Aberrant catecholamine utilization by macrophages in cystic fibrosis.* H. Ozuna, J. Lyles, J. Chandler, A. Murphy, I. Miralda Molina, S. Durfey, J.Moran, M. Shrestha, B. Kopp.

Poster 140: *A randomized controlled study of sildenafil to treat exercise intolerance in people with moderate to severe CF lung disease.* G. Warren, R. Crandall, M. Strand, A. Wilson, R. Harris, J. Taylor-Cousar

Poster 148: *Chronic cystic fibrosis airway disease is driven by MALAT1+ extracellular vesicles via an HDAC11-dependent mechanism.* B. Dobosh, L. Slimmen, D. Luthra, E. Browne, S. Padmanabhan, Z. Li, J. Hosten, P. Kumar, M. Parrilla, M. Aldeco, C. Leese-Thompson, A. Terwindt, D. Moncada Giraldo,, R. Tirouvanziam.

Poster 158: *Hyperglycemia differentially affects neutrophil transmigration across CF and non-CF bronchial epithelial monolayers and is sensitive to CFTR modulator therapies.* G. Cui, A. Vazquez Cegla, J. Brown, K. Jones, R. Reed, R. Tirouvanziam, M. Koval, N. McCarty.

Poster 236: *Amplifying correction of CFTR class I and II variants by tuning ribosomal protein expression.* A.Winters, E. Freestone, Y. Yang, J. Jackson, C. Foye, M. Lopes-Pacheco, S. Santos, J. Rodgers, J. Hartman, E. Sorscher, K. Oliver.

Poster 272: *High-throughput screening methods to discover new ribosomal inhibitors that rescue multiple classes of CFTR variants.* J. Jackson, C. Foye, A. Winters, E. Freestone, M. Lopes-Pacheco, L.Huang, D. Patel, C. Buarque, Y.Du, K. Oliver.

Poster 288: *Evidence against synonymous polymorphism neutrality with rare CFTR variants that display altered modulator responsiveness and clinical phenotype.* M. Lopes-Pacheco, C. Foye, A. Winters, D. Joshi, G. Bavia Bampi, R. Rauscher, K. Raraigh, G. Cutting, E. Sorscher, Z. Ignatova, K. Oliver.

Poster 302: *Role of cholesterol on CFTR single channel characteristics and potential cholesterol binding domains.* J. Brown, G. Cui, K. Jones, N. McCarty.

Poster 320: *An optimized method for culturing primary hNE with improved performance for CFTR theratyping studies.* Y.Ma, S.Wu, L. Yang, J.Wang, Z. Hu, M. Luo, X. Liu, J. Engelhardt.

Poster 326: *Elucidating molecular and environmental factors that drive variability in cystic fibrosis phenotype expression.* E. Freestone, J.White, C. Foye, J. Jackson, M. Lopes-Pacheco, B. Kopp.

Poster 400: *Studying the intersectionality of having CF and being a gender or sexual minority: recruitment and baseline characteristics of the PRIDE-CFcohort.* G. Sawicki, J. Greenberg, K. Kidd, R. Salyer, R. Jain, J. Palla, V. Tangpricha, A. Prangley, O. Stransky, N. Tran, J. Obedin-Maliver, A. Flentje, T. Kazmerski, P. Community Partner Group, M. Lunn

Poster 438: *Podcasts as cystic fibrosis patient education: A pilot study.* K. Ross, S. Gillespie, E. Pinto Taylor, R. Linnemann.

Poster 448: *Bridging gaps in research: empowering research coordinators to strengthen patient partnerships and support diverse participants in cystic fibrosis research.* M.Mann, B. Middour-Oxler, P. Burks, C. Swope, L. Katz, C. George.

Poster 558: *Dietary linoleic acid is associated with increased adiposity in adults with cystic fibrosis not taking CFTR modulators.* M. Schor, L. Gonzalez Ramirez, P. Suppakitjanusant, P. Nesbeth, T. Burley, W. Qian, K. Easley, W. Hunt, A. Stecenko, E. Ivie, B. Cousineau, T. Ziegler, J. Alvarez.

Poster 624: *Modifiable predictors of beta-cell function in adults with cystic fibrosis: the role of body composition and sugar intake.* T. Daley, J. Alvarez, S. Zaveri, D. Stefanovski, L. Gonzalez Ramirez, P. Vellanki, T. Ziegler, A. Stecenko, H. Huang, S. Gillespie, W. Hunt, V. Stallings, A. Kelly.

Poster 680: *Evaluation of testosterone levels in males with cystic fibrosis before and after initiation of elexacaftor/tezacaftor/ivacaftor: data from the PROMISE study.* S. Park, S. Abid, M. Lee, H. Upreti, D. Nichols, S. Sagel, A. Kelly, C. Chan, D. Vellez, V. Tangpricha, F. Khan, G. Solomon, R. Jain.

Poster 692: *Screening for diabetes and pre-diabetes in cystic fibrosis using a non-fasting 50 g 1 hour oral glucose challenge test.* M. Maher, T. Vigers, C. Kohler, A. Stecenko, A. Moran, C. Chan, L. Phillips.

Poster 708: *Body fat distribution impacts glucose and insulin secretory indices in people with cystic fibrosis.* L. Gonzalez Ramirez, C. Drake, A. Goss, T. Daley, P. Vellanki, A. Stecenko, P. Sharma, S. Roh, D. Stefanovski, V. Stallings, W. Hunt, S. Zaveri, T. Ziegler, J. Alvarez.

Poster 788: *Increasing the flu vaccination rate in an adult cystic fibrosis clinic.* L. Anderson.

Poster 814: *eQUIP-CR: a standardized quality improvement approach to optimize clinical research site performance.* R. Joshi, H. Stapp, S. Lazaro, E. Carrick, N. Purohit, N. Wimmer, V. Taskar, K. McKie, C. Forsee.

Poster 824: *The preliminary experience involving the cystic fibrosis collaborative adjustments to routine clinical examinations via MODification of Duration to the next Encounter (CF CARE MODEL) visit tool.* J. Finklea, W. Apraku, Y. Ma, K. Lowe, A. Keller, B. Buehler, J. Mathew, P. Do, C. Merlo, K. Riekert, W. Hunt.

Saturday, October 25, 2025

Time / Location	Topic / Representative
7:45 - 9:45 am PDT Location: Terrace Suite	W31.1- Experimentally evolving a Staphylococcus aureus CF isolate to resist its co-isolated Pseudomonas aeruginosa Speaker: Justin Luu –Emory
8:00 - 9:15 am PDT Location: 323-325	CC06--It's Complicated: A Review of Complex Patients Therapies & Outcomes Chair: Amy Pridgen, PT MPT – Children's Healthcare of Atlanta
8:00 - 9:15 am PDT Location: 447-448	CC05.5- Patient 1: Latina Patient with a Complex Social History & Insurance Barriers that Affected Care & Outcomes Speaker: Laura C. Anderson, BSN, RN, AMB-BC – Emory Healthcare
8:15 - 9:45 am PDT Location: Theater A Exhibit Hall	TPS06.7- Dietary linoleic acid is associated with increased adiposity in adults with CF not taking CFTR modulators Speaker: Matthea E. Schor – Emory University
8:15 - 9:45 am PDT Location: Theater A Exhibit Hall	TPS06.5- Dynamic time warping analysis of continuous glucose monitoring reveals significant dysglycemia that is underestimated by oral glucose tolerance test classification Speaker: Jiafeng Song, M.Sc. – Duke University
10:15 am - 12:15 pm PDT Location: Ballroom 3	S27.3- NTM Phages Speaker: Katherine Wetzel, PhD – Georgia State University
12:30 - 2:00 pm PDT Location: 345-346	RT1.12- Understanding the Presence of DGBIs Amidst GI Manifestations of CF Facilitator: Vivek K. Shenoy, MD – Emory/Children's Healthcare of Atlanta
12:30 - 2:00 pm PDT Location: Elliot Bay	RT2.1- Neurodivergence & Impact on Nutrition Facilitator: Caitlin Bascle, RDN, LD – Emory Healthcare
12:30 - 2:00 pm PDT Location: Elliot Bay	RT2.8- Cell & Animal Models for Gene Therapy Applications Facilitator: Nael A. McCarty, PhD – Emory University
12:30 - 2:00 pm PDT Location:	LL09--Different Plans Toward the Same Destination: Tailoring Treatment to Patient Preferences Speaker: Christopher F. Drescher, PhD – Medical College of Georgia/Augusta University